Sobre este pódcast
Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.
270 episodios · Levenswetenschappen
BioSpace
Último episodioThe decisions behind scientific progress
Sobre este pódcast
Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.
Episodios recientes
- J&J’s disappointing Q3, RevMed’s subgroup data, BMS’ ‘mixed’ results, Caribou’s cutback14 oct · 20 min
- Beyond equity: Why venture debt is reshaping European biotech8 oct · 23 min
- Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more7 oct · 24 min
- The race for access: How the FAIR Act could reclaim U.S. biotech leadership1 oct · 20 min
- AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll30 sept · 20 min
- How radioligand therapy is rewriting cancer care24 sept · 16 min
- Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz23 sept · 21 min
- When vision fades: Rethinking wet AMD and the durability gap17 sept · 22 min
- FDA hears input on psychedelics, PDUFA, lung cancer’s next-gen therapies boost survival16 sept · 22 min
- Novo’s canned heart disease trials, Novartis’ clinical fails, first approval for Alexander disease9 sept · 20 min
sharemy.show/es/biospace
Para un cartel o una diapositiva.